ZA201308681B - Methods of treating multipkle sclerosis and preserving and/or increasing myelin content - Google Patents

Methods of treating multipkle sclerosis and preserving and/or increasing myelin content

Info

Publication number
ZA201308681B
ZA201308681B ZA2013/08681A ZA201308681A ZA201308681B ZA 201308681 B ZA201308681 B ZA 201308681B ZA 2013/08681 A ZA2013/08681 A ZA 2013/08681A ZA 201308681 A ZA201308681 A ZA 201308681A ZA 201308681 B ZA201308681 B ZA 201308681B
Authority
ZA
South Africa
Prior art keywords
multipkle
sclerosis
preserving
treating
methods
Prior art date
Application number
ZA2013/08681A
Other languages
English (en)
Inventor
Gilmore O'neill
Alfred Sandrock
Katherine Dawson
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47217796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201308681(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of ZA201308681B publication Critical patent/ZA201308681B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA2013/08681A 2011-05-26 2013-11-19 Methods of treating multipkle sclerosis and preserving and/or increasing myelin content ZA201308681B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161490572P 2011-05-26 2011-05-26
US201261625624P 2012-04-17 2012-04-17
PCT/US2012/039721 WO2012162669A1 (en) 2011-05-26 2012-05-25 Methods of treating multiple sclerosis and preserving and/or increasing myelin content

Publications (1)

Publication Number Publication Date
ZA201308681B true ZA201308681B (en) 2017-11-29

Family

ID=47217796

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2013/08681A ZA201308681B (en) 2011-05-26 2013-11-19 Methods of treating multipkle sclerosis and preserving and/or increasing myelin content

Country Status (19)

Country Link
US (1) US20140163100A1 (enExample)
EP (1) EP2713724A4 (enExample)
JP (1) JP2014515373A (enExample)
KR (1) KR20140036257A (enExample)
CN (1) CN103732062A (enExample)
AU (1) AU2012258558A1 (enExample)
BR (1) BR112013030169A2 (enExample)
CA (1) CA2836480A1 (enExample)
CL (1) CL2013003358A1 (enExample)
CO (1) CO6811862A2 (enExample)
EA (1) EA201391578A1 (enExample)
EC (1) ECSP13013117A (enExample)
IL (1) IL229448A0 (enExample)
MX (1) MX2013013781A (enExample)
PE (1) PE20141316A1 (enExample)
PH (1) PH12013502443A1 (enExample)
SG (1) SG195049A1 (enExample)
WO (1) WO2012162669A1 (enExample)
ZA (1) ZA201308681B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004010531T2 (de) 2003-09-09 2008-07-03 Fumapharm Ag Verwendung von fumarsäure-derivaten zur behandlung von herzinsuffizienz und asthma
EP3470064A1 (en) 2004-10-08 2019-04-17 Fwp Ip Aps Controlled release pharmaceutical compositions comprising a fumaric acid ester
NZ608196A (en) 2008-08-19 2014-09-26 Xenoport Inc Prodrugs of methyl, hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
MX355421B (es) 2011-06-08 2018-04-18 Biogen Ma Inc Proceso para preparar fumarato de dimetilo cristalino y de alta pureza.
EP2887934A1 (en) 2012-08-22 2015-07-01 XenoPort, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
US20140348915A9 (en) 2012-08-22 2014-11-27 Xenoport, Inc. Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof
US20140057918A1 (en) * 2012-08-22 2014-02-27 Xenoport, Inc. Methods of Use for Monomethyl Fumarate and Prodrugs Thereof
EP3566701A1 (en) 2012-12-21 2019-11-13 Biogen MA Inc. Deuterium substituted fumarate derivatives
ES2955137T3 (es) 2013-03-14 2023-11-28 Alkermes Pharma Ireland Ltd Profármacos de fumaratos y su uso en el tratamiento de diversas enfermedades
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
US10179118B2 (en) 2013-03-24 2019-01-15 Arbor Pharmaceuticals, Llc Pharmaceutical compositions of dimethyl fumarate
WO2014197860A1 (en) 2013-06-07 2014-12-11 Xenoport, Inc. Method of making monomethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
US9416096B2 (en) 2013-09-06 2016-08-16 Xenoport, Inc. Crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and use
CN103724198A (zh) * 2013-11-28 2014-04-16 镇江圣安医药有限公司 富马酸二甲酯的新型衍生物及其应用
CA2940845C (en) 2014-02-24 2019-09-24 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US9326965B2 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
AU2014414316B2 (en) * 2014-10-27 2020-04-09 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
MA40985A (fr) * 2014-11-17 2017-09-26 Biogen Ma Inc Méthodes de traitement de la sclérose en plaques
MA41139A (fr) * 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
KR102590068B1 (ko) 2014-12-11 2023-10-16 액테리온 파마슈티칼 리미티드 선택적 s1p1 수용체 효능제에 대한 투약 섭생
WO2021142062A1 (en) 2020-01-10 2021-07-15 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19721099C2 (de) * 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
CA2478458A1 (en) * 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
CN101056624A (zh) * 2004-10-08 2007-10-17 Adi技术制药股份公司 包含富马酸酯的控释药物组合物
EP1951206A1 (en) * 2005-10-07 2008-08-06 Aditech Pharma AB Controlled release pharmaceutical compositions comprising a fumaric acid ester
PT2653873T (pt) * 2007-02-08 2022-07-26 Biogen Ma Inc Composições e utilizações para o tratamento de esclerose múltipla
LT2139467T (lt) * 2007-02-08 2016-10-10 Biogen Ma Inc. Neuroapsauga, sergant demielinizuojančia liga
NZ608196A (en) * 2008-08-19 2014-09-26 Xenoport Inc Prodrugs of methyl, hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
CN102427727A (zh) * 2009-04-29 2012-04-25 比奥根艾迪克Ma公司 神经变性和神经炎症的治疗

Also Published As

Publication number Publication date
PE20141316A1 (es) 2014-10-01
CL2013003358A1 (es) 2014-08-01
US20140163100A1 (en) 2014-06-12
MX2013013781A (es) 2014-01-08
AU2012258558A1 (en) 2013-05-02
BR112013030169A2 (pt) 2016-08-09
KR20140036257A (ko) 2014-03-25
WO2012162669A1 (en) 2012-11-29
SG195049A1 (en) 2013-12-30
EP2713724A1 (en) 2014-04-09
EA201391578A1 (ru) 2014-05-30
EP2713724A4 (en) 2015-03-11
IL229448A0 (en) 2014-01-30
CO6811862A2 (es) 2013-12-16
JP2014515373A (ja) 2014-06-30
CA2836480A1 (en) 2012-11-29
CN103732062A (zh) 2014-04-16
ECSP13013117A (es) 2014-06-30
PH12013502443A1 (en) 2019-03-22

Similar Documents

Publication Publication Date Title
ZA201308681B (en) Methods of treating multipkle sclerosis and preserving and/or increasing myelin content
ZA201404929B (en) Compositions and methods for surface treatment with lipases
IL237528B (en) Methods for preventing and treating preeclampsia
EP2847152A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF METABOLIC SYNDROME
ZA201403378B (en) Treatment of multiple sclerosis with combination of laquinimod and fingolimod
EP2771030A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF PROTEINOPATHIES
ZA201305783B (en) Composition and methods for treating cardiovascular diseases
PL2737306T3 (pl) Zakodowane bioczujniki i sposoby ich wytwarzania
HUE039170T2 (hu) Eljárás videó kódolásra és videó tartalom tárolásra
IL225246A0 (en) Methods for speeding up the restoration of skin normality and for treatment of impetigo
GB201320723D0 (en) Composition and methods of treatment
GB201217296D0 (en) Method of treatment and/or prevention
EP2665481A4 (en) METHOD AND COMPOSITIONS FOR TREATING METABOLIC SYNDROME
EP2572730A4 (en) PROCESS FOR PROPHYLAXIS OR TREATMENT OF METABOLIC SYNDROME
GB201103293D0 (en) Treatment and prevention of malaria
PT2702992T (pt) Uso de melatonina para tratamento e/ou prevenção da mucosite
EP2704702A4 (en) COMPOSITION AND METHOD OF TREATING DIABETES
PL3082845T3 (pl) Sposoby i kompozycje do leczenia neuropatii obwodowych
PL2731616T3 (pl) Sposób profilaktyki i leczenia sepsy
PL2936151T3 (pl) Sposoby leczenia i/lub ograniczania rozwoju cukrzycy
EP2726079A4 (en) METHOD OF ADMINISTRATION AND TREATMENT
ZA201408062B (en) Compositions and methods for the treatment of multiple sclerosis
ZA201408065B (en) Compositions and methods for the treatment of diabetes
IL229438A0 (en) Methods for treating obesity and/or metabolic syndrome
ZA201408053B (en) Compositions and methods for the treatment of metabolic syndrome